Landmark TrialRCTRandomized Controlled Trial
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
New England Journal of Medicine2010IF: 25.4
F. Stephen Hodi Steven O’Day David F. McDermott Robert Weber Jeffrey A. Sosman John B.A.G. Haanen René González Caroline Robert Dirk Schadendorf Jessica C. Hassel Wallace Akerley Alfons J.M. van den Eertwegh Jose Lutzky Paul Lorigan Julia Vaübel Gerald P. Linette David Hogg Christian H. Ottensmeier Célèste Lebbé Christian Peschel Ian Quirt Joseph I. Clark Jedd D. Wolchok Jeffrey S. Weber Jason Tian Michael Yellin Geoffrey Nichol Axel Hoos Walter J. Urba
Abstract
Ipilimumab, with or without a gp100 peptide vaccine, as compared with gp100 alone, improved overall survival in patients with previously treated metastatic melanoma. Adverse events can be severe, long-lasting, or both, but most are reversible with appropriate treatment. (Funded by Medarex and Bristol-Myers Squibb; ClinicalTrials.gov number, NCT00094653.)